Chemoradiation-Induced Oral Mucositis (CRIOM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Oral mucositis is an important complication in non-surgical cancer treatments. It represents the major complication in radiotherapy of tumors located in head and neck areas. Mucositis manifests itself as erythema, edema, or ulceration that can be accompanied by a mild burning sensation. Radiation-induced mucositis may involve any radiation-exposed area, including the hard palate, lip, buccal mucosa, tongue ventrolateral aspect, and mouth base. The direct mechanisms of irradiation include interrupting the cell renewal cycle and apoptosis. The indirect mechanisms leading to oral mucositis include the release of inflammation mediators, the loss of protective salivary role, and neutropenia induced by the treatment.
·
Oropharyngeal mucositis occurs in more than 85
to 92% of patients who receive radiation and/or chemotherapy for head and neck
tumors.
·
According to the research, ~85% of patients
undergoing radiation therapy showed oropharyngeal mucositis, amongst which ~30%
developed severe oropharyngeal mucositis.
Thelansis’s “Chemoradiation-Induced
Oral Mucositis (CRIOM) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Chemoradiation-Induced
Oral Mucositis (CRIOM) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Chemoradiation-Induced Oral Mucositis (CRIOM) across 8 MM market from the
centre of Excellence/ Public/ Private hospitals participated in the study.
Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm, and Unmet needs.
Chemoradiation-Induced Oral Mucositis
(CRIOM) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment